Last reviewed · How we verify
Lapatinib and Sorafenib
At a glance
| Generic name | Lapatinib and Sorafenib |
|---|---|
| Also known as | Tykerb and Nexavar |
| Sponsor | Istituto Clinico Humanitas |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (PHASE2)
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (PHASE2)
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Bevacizumab in Multiple Phase I Combinations (PHASE1)
- Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (PHASE2)
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (PHASE2)
- The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lapatinib and Sorafenib CI brief — competitive landscape report
- Lapatinib and Sorafenib updates RSS · CI watch RSS
- Istituto Clinico Humanitas portfolio CI